My research group works on molecular pathology, genetics and progression of leukaemia and lymphomas, aiming to improve on current diagnostic, prognostic and treatment strategies.
Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet (2016) 48(2):183-8. PMID: 26691987
Disease evolution and outcomes in familial AML with germline CEBPA mutations. Blood (2015) 126(10):1214-23. PMID: 26162409
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet (2014) 46(2):176-81. PMID: 24362818
Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med (2004) 351(23):2403-7. PMID: 15575056
In lymphoma our focus is a B cell malignancy called follicular lymphoma and the (epi)genomic changes responsible for the onset and severity of the disease. Although these tumours are chemo-sensitive, the disease is incurable, with many patients experiencing several episodes of relapse before the disease becomes refractory to treatment. We have traced the genetic changes in these tumours over time and uncovered a highly complex pattern of tumour evolution, consistent with the existence of a common progenitor B cell (CPC) population from which each new episode of disease is thought to arise. Current studies are focusing on characterising this CPC population and the use of KDM5 inhibition as a means of subverting the effects of mutations in the histone methyltransferase, KMT2D, that arise in >70% of FL tumours.
In leukaemia we have a longstanding interest in the study of familial acute myeloid leukaemia (AML) and myelodysplasia. These studies are important both to the individual families and are providing new insights into the molecular evolution of AML, the patterns by which mutations arise and an explanation for the clinical heterogeneity that exists both within and between families. We also have a parallel programme in poor risk AML where outcomes have changed little over the past 40 years, and are following a multi-omic strategy to profile these AMLs and gain a deeper understanding of the disease in this group of patients.
Watch Professor Fitzgibbon’s interview with the MDS UK Patient Support Group at the UK MDS Education Forum.
Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma (Leukemia, (2018), 32, 5, (1261-1265), 10.1038/s41375-018-0043-y) Araf S, Wang J, Korfi K et al. Leukemia (2019) 33(7) 1540
Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant. Araf S, Wang J, Ashton-Key M et al. Haematologica (2019) 104(1) e174-e177
Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML Jakobsen JS, Laursen LG, Schuster MB et al. Science Advances (2019) 5(7)
GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML Al Seraihi AF, Rio-Machin A, Tawana K et al. Leukemia (2018) 32(7) 2502-2507
homozygous OB-fold variants in telomere protein TPP1 are associated with dyskeratosis congenita-like phenotypes DOKAL I, TUMMALA H, VULLIAMY T Blood (2018) 132(1) 1349-1353
Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells Casado P, Wilkes EH, Miraki-Moud F et al. Leukemia (2018) 32(7) 1818-1822
Rituximab as a first step in tackling transformation Okosun J, Kridel R, Fitzgibbon J The Lancet Haematology (2018) 5(7) e326-e327
Precision medicine and lymphoma. Heward JA, Kumar EA, Korfi K et al. Curr Opin Hematol (2018) 25(1) 329-334
Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma Araf S, Wang J, Korfi K et al. Leukemia (2018) 32(7) 1258-1263
Predicting early relapse in follicular lymphoma: have we turned a corner? Araf S, Okosun J, Fitzgibbon J The Lancet Oncology (2018) 19(7) 441-442For additional publications, please click here
I joined Barts and the London Medical School as a Research Fellow in Medical Oncology in 1997, becoming Senior Lecturer in 2004, Reader in 2009 and Professor in 2013. I received my BA degree in Genetics at Trinity College Dublin in 1989 before completing my PhD studies on the Genetics of Tuberous Sclerosis at University College London in 1993.